MedTrace Logo

To Evaluate the Efficacy and Safety of DW1903 in Acute and Chronic Gastritis Patient

NCT05163756 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 332

Last updated 2021-12-20

No results posted yet for this study

Summary

A Multi-center, Double-blind, Randomized, Parallel, Active-controlled, Non-inferiority, Phase III Clinical Trial to Evaluate the Efficacy and Safety of DW1903 in Patients with Gastritis

Conditions

  • Gastritis Acute
  • Gastritis Chronic

Interventions

DRUG

DW1903

q.d. PO, DW1903 + Placebo of DW1903-R1

DRUG

DW1903-R1

q.d. PO, Placebo of DW1903 + DW1903-R1

Sponsors & Collaborators

  • Daewon Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-25
Primary Completion
2021-04-27
Completion
2021-05-10

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05163756 on ClinicalTrials.gov